Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension.

ABSTRACT:

Background

Recently studied therapies for pulmonary arterial hypertension (PAH) have improved outcomes among populations of patients, but little is known about which patients are most likely to respond to specific treatments. Differences in endothelin-1 biology between sexes and between whites and blacks may lead to differences in patients' responses to treatment with endothelin receptor antagonists (ERAs).

Methods

We conducted pooled analyses of deidentified, patient-level data from six randomized placebo-controlled trials of ERAs submitted to the US Food and Drug Administration to elucidate heterogeneity in treatment response. We estimated the interaction between treatment assignment (ERA vs placebo) and sex and between treatment and white or black race in terms of the cha

SUBMITTER: Gabler NB 

PROVIDER: S-EPMC5991545 | biostudies-literature | 2012 Jan

REPOSITORIES: biostudies-literature